H. Granstam-Björneklett

Immune response, depression and fatigue in relation to support intervention in mammary cancer patients

M. Lekander, H. Mellstedt, L. Bergkvist, 2007, Supportive Care in Cancer.

NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy

M. Lekander, H. Mellstedt, B. Nilsson, 2007, British Journal of Cancer.

Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study

M. Lekander, H. Mellstedt, L. Bergkvist, 2008, Cancer Immunology, Immunotherapy.

Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The SOLD Randomized Clinical Trial

P. Neven, H. Wildiers, H. Joensuu, 2018, JAMA oncology.

Abstract GS3-04: A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study)

P. Neven, H. Wildiers, H. Joensuu, 2018 .

Existential aspects are neglected in the evaluation of support-intervention in breast cancer patients

P. Strang, L. Bergkvist, C. Lindemalm, 2012, Acta oncologica.